Loading...
•
Sep 30, 2025
Castle Biosciences Q3 2025 Earnings Report
Estimated Revenue:$71M
-13.6% YoY
Estimated EPS:-$0.45
635.3% YoY
Key Takeaways
Castle Biosciences delivered a strong third quarter in 2025, achieving $83 million in revenue and a total test report volume of 26,841. The company saw significant growth in its core dermatologic and gastrointestinal testing franchises, with DecisionDx-Melanoma and TissueCypher each surpassing 10,000 test reports. This strong performance led to an increase in the full-year 2025 revenue guidance.
Achieved $83 million in revenue for Q3 2025, demonstrating strong financial performance.
Total test report volume reached 26,841 in Q3 2025, indicating increased adoption of its tests.
DecisionDx-Melanoma and TissueCypher each surpassed 10,000 test reports for the first time in a single quarter.
Raised full-year 2025 revenue guidance to $327-335 million, up from the previous range of $310-320 million.
Forward Guidance
Castle Biosciences is raising its full-year 2025 revenue guidance due to strong performance in the third quarter and continued momentum in its core testing franchises.
Positive Outlook
- Raised full-year 2025 total revenue guidance to $327-335 million, up from $310-320 million.
- Strong execution and expanding adoption of core tests are expected to continue.
- Launch of AdvanceAD-Tx™ is expected to address a significant unmet need in clinical dermatology.
- Continued growth anticipated in core dermatologic and gastrointestinal testing franchises.
- Positive momentum from Q3 2025 is expected to carry into the rest of the year.
Loading...
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...